What did @krystynalaynefloyd actually say?
She reported losing 8.9 pounds over four weeks on compounded semaglutide at the 0.25 mg starting dose, with minimal side effects. Now she is moving to 0.5 mg. She also mentioned returning hunger as her signal to increase the dose, and she was transparent that week four produced no weight loss, just maintenance.
That is actually a reasonably honest account. She did not exaggerate her results, she acknowledged a stall, and she did not make any disease-cure claims. She did not provide medical advice beyond describing her own experience. The telehealth provider she named, Ivรญm Health, is one of several platforms dispensing compounded semaglutide, and she pointed viewers to a separate video for pricing, not a referral link embedded in this one.
Does the science back this up?
The 8.9-pound loss over four weeks is plausible but sits at the higher end of what clinical data predicts at a 0.25 mg dose. That said, early rapid loss is well-documented and is partly water weight and glycogen depletion, not all fat.
The landmark STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants on 2.4 mg semaglutide lost roughly 15% of body weight over 68 weeks. At week four in that trial, losses were modest. Real-world results at the titration phase vary considerably by starting weight, diet, and activity. A 2023 retrospective analysis by Ghusn et al. in Obesity Pillars found early responders in the first month sometimes lost 3-5% of body weight, which is consistent with her numbers depending on her starting weight. Returning hunger at the end of a dose cycle is also well-supported: semaglutide has a half-life of roughly seven days, and appetite suppression can wane as trough levels drop before the next injection.
What did they get right, and what is missing?
She got the dose titration schedule right. Standard semaglutide protocols start at 0.25 mg for four weeks before moving to 0.5 mg, which mirrors FDA-approved Ozempic dosing guidance. Her framing of hunger returning as a signal that the dose needs adjusting is consistent with how GLP-1 receptor agonists work pharmacologically.
What she did not address, and this matters, is that compounded semaglutide is not FDA-approved. The FDA has repeatedly flagged concerns about compounded versions, including inconsistent potency and the use of semaglutide salt forms rather than the base compound used in Wegovy and Ozempic. A 2024 FDA safety communication specifically warned that compounded semaglutide products have not been shown to be safe or effective. That does not mean they do not work for some people. It means the quality control data simply does not exist the way it does for brand-name products. She presents her compounded product as equivalent to the branded drug, and that is an assumption the evidence does not fully support.
What should you actually know?
A four-week weight loss update on TikTok is not a clinical trial, and it should not be treated like one. Early losses on GLP-1 medications look dramatic partly because they are front-loaded. The hard part is sustained adherence over months, managing side effects at higher doses, and not attributing all of the loss to the drug when caloric restriction is doing substantial work simultaneously.
If you are considering compounded semaglutide, the central issue is sourcing and oversight. Telehealth platforms vary significantly in how they screen patients, monitor labs, and adjust doses. The FDA placed Novo Nordisk semaglutide back on the shortage list in 2023, which temporarily allowed compounding, but the legal and regulatory status of these products has been shifting. A 2024 review by Frellick in Medscape noted ongoing enforcement actions against compounding pharmacies with inconsistent product quality. The bottom line: compounded semaglutide may deliver real weight loss results, but assuming it is interchangeable with a brand-name product is not a safe leap to make based on one creator's four-week results.